Clinical Trial Search

Primary: Clinical Success in Patients With Moderate and Severe Scalp Psoriasis — 41; 43 Participants — p=0.4557

Primary: Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 Items (ADAS-Cog-11) Score Change From Baseline to Week 24 — 0.39; 0.75 units on a scale — p=0.2249

Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) During the Study Period — 91.2 percentage of participants

Primary: The Primary Efficacy Endpoint is a Responder Rate Analysis, Where a Responder is Defined as a Patient With no More Than 2 of 6 Months With Any Evidence of Illicit Opioid…

Primary: Percentage of Patients With Drug-related Adverse Events (AEs) During the Treatment Phase — 21.3; 20.4; 17.6 Percentage of patients (%)

Primary: Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms — -0.26; -0.53; -0.56; -0.67 units on a scale

Primary: Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms — -0.24; -0.59; -0.68; -0.62 units on a scale

Primary: 3-year Overall Survival Rate — 0.965; 0.843; 0.870 proportion of patients — p=0.35

Primary: Primary Effectiveness Endpoint Success Number of Successes (Subjects That Had no Inter-operative CSF Leak Following Valsalva Maneuver and no CSF Leak or…

Primary: Percentage of Participants Who Experience at Least 1 Adverse Event (AE) — 72.8; 76.2 Percentage of Participants

Primary: Number of Participants With a Decrease in the Number of Apnea and/or Hypopnea Events to <5 Per Hour of Sleep — 5; 3 Participants — p==0.946

Primary: Number of Participants Monitored for Long-Term Safety of Valbenazine — 45; 107; 11 Participants

Primary: Time to Failure of First Line Therapy or Death — 48; 32; 26 Participants — p=0.02

Primary: Number of Participants With Early Clinical Response — 315; 297; 26; 32 Participants

Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days — -2.81; -4.73; -4.57 Days — p=<.001